Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

NCT03870399 is registered in ClinicalTrials.gov with AC Camargo Cancer Center as lead sponsor.

NCT NCT03870399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03870399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Lead sponsor
AC Camargo Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2019
Completion date
May 13, 2023
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor positive tumor, neuroendocrine tumors, progesterone receptor positive tumor